Search    Show all


1 People found

filters applied:

Details

1 / 1

EMBO Member

Marc Feldmann

University of Oxford | United Kingdom

EMBO 2006

Uncovering new therapeutic targets

Previous research focusing on rate limiting steps in the pathogenesis of rheumatoid arthritis uncovered TNF-alpha as the key mediator and led to development of anti-TNF therapy, currently the best-selling pharmaceuticals. I aim to get closer to a cure by defining other rate limiting steps. Discovering TNF as a target was based on using human disease tissue, and working with colleagues analysing human disease tissue we detected therapeutic targets in atherosclerosis, fractures and fibrosis.

Keywords: Immunotherapy / anti-TNF / rheumatoid arthritis / autoimmune diseases / cytokines

Subject area(s): Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology

EMBOwords